2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-Bias Bispecific Fusion Protein) in First-Line Advanced NSCLC
The 3 mg/kg and 3/1.5 mg/kg regimens showed strong response and survival signals, while safety remained manageable, Innovent said.
- On Monday, Innovent Biologics presented updated Phase 1 data at the 2026 American Society of Clinical Oncology meeting, demonstrating efficacy for IBI363 in advanced first-line non-small cell lung cancer .
- Takeda and Innovent Biologics co-developed IBI363, which targets the PD-1/IL-2 pathway to reinvigorate exhausted T cells and reverse immune suppression in the tumor microenvironment, addressing a key bottleneck in immunotherapy-resistant disease.
- In the 3/1.5 mg/kg dose group , IBI363 achieved an objective response rate of 86.4%, a confirmed response rate of 81.8%, and 100% disease control rate, particularly in tumors with low PD-L1 expression.
- The 3/1.5 mg/kg regimen is recommended for further clinical investigation; Grade 3 treatment-related adverse events occurred in 65.2% of patients, representing a manageable safety profile enabling durable treatment benefits.
- Currently, the second stage compares IBI363 plus chemotherapy against pembrolizumab plus chemotherapy as first-line treatment for advanced NSCLC across all PD-L1 expression levels.
30 Articles
30 Articles
Aspen Daily News
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLCIBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communications, initiation of a…
The Billings Gazette
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95%…
Innovent presents long-term survival data for IBI363 in immunotherapy-resistant NSCLC
SAN FRANCISCO and SUZHOU, China, June 1, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced the preliminary results from a PoC clinical study of its global first-in-class PD-1/IL-2α-bias …
Coverage Details
Bias Distribution
- 90% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
